113984-68-2

Upstream product

• 371-41-5 4-Fluorophenol 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 459-60-9 1-fluoro-4-methoxybenzene 
• 113984-67-1 5-((tert-butyldimethylsilyl)oxy)-2-fluorobenzaldehyde 
• 72358-73-7 (4-fluorophenyl) benzenesulfonate 
• 873426-76-7 tert-butyldimethylsilyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl ether 
• 405-51-6 4-fluorophenyl acetate 
• 132362-07-3 (5,7-Bis-benzyloxy-4-fluoro-1H-indol-3-ylmethyl)-trimethyl-ammonium; iodide 
• 132303-37-8 5,7-Bis-benzyloxy-4-fluoro-1H-indole-2-carboxylic acid methyl ester 
• 132303-50-5 (5,7-Bis-benzyloxy-4-fluoro-1H-indol-3-yl)-acetonitrile 
• 132303-40-3 5,7-Bis-benzyloxy-4-fluoro-1H-indole-2-carbaldehyde 
• 132303-53-8 2-(5,7-Bis-benzyloxy-4-fluoro-1H-indol-3-yl)-ethylamine 
• 132303-46-9 (5,7-Bis-benzyloxy-4-fluoro-1H-indol-3-ylmethyl)-dimethyl-amine 
• 132303-43-6 5,7-Bis-benzyloxy-4-fluoro-1H-indole 
• 113984-71-7 2-fluoro-3,5-dimethoxy-benzaldehyde 
• 113984-72-8 3,5-Bis-benzyloxy-2-fluoro-benzaldehyde 

Relevant academic research and scientific papers

COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS

Provided herein is a compound of formula (XXXII) or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer thereof or a physiologically functional derivative thereof, wherein R1, R2, R3, G, A, E, n, p, and q are defined herein. Also provided herein are compositions comprising a compound of formula (XXXII), and methods of using a compound of formula (XXXII), e.g., in the treatment or prevention of skin disorders.

NFSI/KF mediated mild and chemoselective interconversion of aryl TBDMS ethers to their benzene sulfonate

A one pot protocol for the transformation of aryl TBDMS ethers to corresponding benzene sulfonate esters using NFSI (N-flurobenzenesulfonimide)/KF is described. In situ generation of benzenesulfonyl fluoride directs chemoselective cleavage of aryl silyl ethers over alkyl silyl ethers. Electron withdrawing substituent's on aryl ring provided better yield than donating groups. Protecting groups and sensitive functionalities are well tolerated in this methodology. Thus, commercially available inexpensive reagents, mild reaction conditions and step economy are the advantages of this method.

The effect of solvent accessible surface on Hammett-type dependencies of infinite dilution 29Si and 13C NMR shifts in ring substituted silylated phenols dissolved in chloroform and acetone

Infinite dilution 29Si and 13C NMR chemical shifts were determined from concentration dependencies of the shifts in dilute chloroform and acetone solutions of para substituted O-silylated phenols, 4-R-C6H4-O-SiR′2R″ (R = Me, MeO, H, F, Cl, NMe2, NH2, and CF3), where the silyl part included groups of different sizes: dimethylsilyl (R′ = Me, R″ = H), trimethylsilyl (R′ = R″ = Me), tert-butyldimethylsilyl (R′ = Me, R″ = CMe3), and tert-butyldiphenylsilyl (R′ = C6H5, R″ = CMe3). Dependencies of silicon and C-1 carbon chemical shifts on Hammett substituent constants are discussed. It is shown that the substituent sensitivity of these chemical shifts is reduced by association with chloroform, the reduction being proportional to the solvent accessible surface of the oxygen atom in the Si-O-C link. Copyright

SUBSTITUTED DIHYDROPYRIDINES AND METHODS OF USE

Compounds are provided that are modulators of the C5a receptor. The compounds are substituted dihydropyridines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activtation of C5a receptors.

Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity

The discovery of a highly potent and selective tissue factor/factor VIIa inhibitor is described. Upon oral administration of its double prodrug in the guinea pig, a dose-dependent antithrombotic effect is observed in an established model of arterial throm

Synthesis and Adrenergic Activity of Ring-Fluorinated Phenylephrines

2-Fluoro-, 4-fluoro-, and 6-fluorophenylephrine (6-FPE) were synthesized from the corresponding fluorinated 3-hydroxybenzaldehydes.New routes to 2-fluoro- and 6-fluoro-3-hydroxybenzaldehydes were developed based on regioselective lithiation of 2- and 4-fluorobenzene ortho to fluorine.As with norepinephrine and isoproterenol analogues, the adrenergic properties of phenylephrine were markedly altered by ring fluorination.The order of potency of the fluoro analogues as α1-adrenergic agonists in the stimulation of contraction of aorticstrips and of phosphatidylinositol turnover and potentiation of cyclic AMP accumulation in guinea pig synaptoneurosomes was 6-FPE > PE > 4-FPE > 2-FPE.The same pattern was observed for the displacement of radioligands specific for α1- and α2-adrenergic receptors on brain membranes.The order of potency for the displacement of 3H>dihydroalprenolol, a β-specific adrenergic ligand from brain membranes, was 2-FPE > 4-FPE = PE >> 6-FPE. 6-FPE was much more selective for α-adrenergic receptors compared to β-receptors than was phenylephrine.A rationale for the observed fluorine-induced alterations in potency and selectivity of the FPEs for α- and β-adrenergic systems is presented based on fluorine-induced conformations due to electrostatic repulsion of fluorine and the benzyl hydroxyl group.